194 related articles for article (PubMed ID: 37529952)
21. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
22. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
23. Autosomal recessive hypophosphatemic rickets type 2; a novel mutation in the ENPP1 gene.
Bitkin EÇ; Aymelek HS
Turk J Pediatr; 2022; 64(3):585-591. PubMed ID: 35899574
[TBL] [Abstract][Full Text] [Related]
24. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
25. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
Saito T; Nishii Y; Yasuda T; Ito N; Suzuki H; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2009 Oct; 161(4):647-51. PubMed ID: 19581284
[TBL] [Abstract][Full Text] [Related]
26. Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency.
Höppner J; Kornak U; Sinningen K; Rutsch F; Oheim R; Grasemann C
Bone; 2021 Dec; 153():116111. PubMed ID: 34252603
[TBL] [Abstract][Full Text] [Related]
27. Genotype-phenotype analysis, and assessment of the importance of the zinc-binding site in PHEX in Japanese patients with X-linked hypophosphatemic rickets using 3D structure modeling.
Ishihara Y; Ohata Y; Takeyari S; Kitaoka T; Fujiwara M; Nakano Y; Yamamoto K; Yamada C; Yamamoto K; Michigami T; Mabe H; Yamaguchi T; Matsui K; Tamada I; Namba N; Yamamoto A; Etoh J; Kawaguchi A; Kosugi R; Ozono K; Kubota T
Bone; 2021 Dec; 153():116135. PubMed ID: 34333162
[TBL] [Abstract][Full Text] [Related]
28. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
[TBL] [Abstract][Full Text] [Related]
29. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
30. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
[TBL] [Abstract][Full Text] [Related]
31. Advances in understanding of phosphate homeostasis and related disorders.
Michigami T
Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
[TBL] [Abstract][Full Text] [Related]
32. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor 23 levels in cord and peripheral blood during early neonatal period as possible predictors of affected offspring of X-linked hypophosphatemic rickets: report of three female cases from two pedigrees.
Nabeshima Y; Sato T; Zukeran H; Komatsu R; Nakano S; Ichihashi Y; Tominaga T; Miwa M; Amano N; Ishii T; Hasegawa T
J Pediatr Endocrinol Metab; 2023 Aug; 36(8):786-790. PubMed ID: 37342899
[TBL] [Abstract][Full Text] [Related]
35. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
37. FGF23-related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case.
Tabei Y; Ohtsu Y; Shimada M; Wada A; Hamajima E; Osawa Y; Takizawa T
Clin Case Rep; 2024 Jan; 12(1):e8420. PubMed ID: 38223518
[TBL] [Abstract][Full Text] [Related]
38. [FGF23-related hypophosphatemic rickets/osteomalacia].
Ito N; Fukumoto S
Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
[TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets.
Capelli S; Donghi V; Maruca K; Vezzoli G; Corbetta S; Brandi ML; Mora S; Weber G
Bone; 2015 Oct; 79():143-9. PubMed ID: 26051471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
